SBFM
Sunshine Biopharma, Inc. (NASDAQ)
Healthcare — Drug Manufacturers - Specialty & Generic
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Price History
Fundamentals
| Market Cap | $4.63M |
| P/E Ratio (TTM) | - |
| Forward P/E | 0.01 |
| EPS (TTM) | $-12.50 |
| Dividend Yield | - |
| Profit Margin | -17.02% |
| Revenue Growth | -9.10% |
| ROE | -27.32% |
| Debt/Equity | 3.46 |
| Recommendation | None |
| Analyst Target | $56.00 |
| Analysts | 1 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 52.0 |
| Beta | 1.31 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $24.30 |
| 52-Week Low | $2.00 |
| 50-Day Avg | $5.29 |
| 200-Day Avg | $11.55 |
| Avg Volume | $1.65M |
| Volume | 2.3K |
Performance Analysis
NEUTRALSBFM presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:30 UTC
Back to Screener Export Report